Soligenix Inc(SNGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:30 PM ET (Korea 10/1 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.27 | Insider Own | 4.59% | Shs Outstand | 21.6M | Perf Week | -6% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 37.5% | Insider Trans | - | Shs Float | 20.8M | Perf Month | -4.74% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.1 | Inst Own | 4.29% | Short Float | 0.98% | Perf Quarter | -8.82% |
| Income | -0.01B | P/S | - | EPS this Y | 81.31% | Inst Trans | 8.08% | Short Ratio | 0.69 | Perf Half Y | -69.32% |
| Sales | 0.00B | P/B | 1.18 | EPS next 5Y | - | ROA | -125.95% | Short Interest | 0.20M | Perf YTD | -72.99% |
| Book/sh | 0.31 | P/C | 0.8 | EPS past 3/5Y | 69.72% 57.52% | ROE | -241.65% | 52W High | -81.62% ($1.97) | Perf Year | -68.79% |
| Cash/sh | 0.45 | P/FCF | - | Sales past 3/5Y | - | ROIC | -149.97% | 52W Low | 29.29% ($0.28) | Perf 3Y | -95.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 66.94% | Gross Margin | - | Volatility(W/M) | 2.98% 4.1% | Perf 5Y | -99.86% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.02 | Perf 10Y | -99.98% |
| Dividend Ex-Date | - | Quick Ratio | 2.77 | EPS Q/Q | 84.88% | Profit Margin | - | RSI (14) | 40.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.77 | Sales Q/Q | - | SMA20 | -2.91% ($0.37) | Beta | 2 | Target Price | $1.5 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/7 | SMA50 | -4.14% ($0.38) | Rel Volume | 0.31 | Prev Close | $0.37 |
| Employees | 14 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 22.58% - | SMA200 | -54.49% ($0.79) | Avg Volume(3M) | 0.29M | Price | $0.36 |
| IPO | 1994/4/4 | Option/Short | No/Yes | Trades | 275 | Volume | 90,289 | Change | -0.82% |
🧫 Soligenix, Inc. is a clinical-stage biotech that addresses both rare diseases and public health vaccines. Its lead pipeline candidate, HyBryte™, is a photodynamic therapy that activates synthetic hypericin with visible light, targeting cutaneous T-cell lymphoma (CTCL) in an ongoing Phase 3 FLASH2 clinical trial. In its public health division, the company also develops vaccine programs such as RiVax® for biodefense and infectious diseases.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded less than usual That is 31% of its average volume.
SNGX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +81.3% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.9%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #527 of 592 in the industry
Based on market cap of $8M.
FAQ
What kind of company is SNGX?
SNGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SNGX?
The market cap of SNGX is approximately $8M, ranking 5,558 within its sector.
What is the 52-week high and low for SNGX?
SNGX has recorded a 52-week high of $1.97 and a low of $0.28.
